Notice Concerning Start Of Phase III Trial Of "Arct-154," A Potential New Class Of mRNA Vaccine For Covid-19, In Japan

Meiji Holdings

13/12/2022 06:06

Dec 13 (Reuters) - Meiji Holdings Co Ltd  2269.T :
    * MEIJI HOLDINGS CO LTD - NOTICE CONCERNING START OF PHASE
III
TRIAL OF "ARCT-154," A POTENTIAL NEW CLASS OF MRNA VACCINE FOR
COVID-19, IN JAPAN

Further company coverage:  2269.T 
 (Reporting by Tokyo newsroom)